PFE - GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B | Benzinga
Wednesday, GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) announced they have restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investment and focus on its respective mRNA development activities.
Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases.
Through this collaboration, GSK and CureVac have vaccine candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development.
All candidates are based on CureVac's proprietary second-generation mRNA backbone.
Also Read: CureVac, GSK Partner Release Data On Influenza Vaccine Study.
GSK will assume full control of developing and manufacturing these candidate vaccines.
GSK will have worldwide rights to commercialize the candidate vaccines.
CureVac will receive an upfront payment of around $430.4 million (400 million euros) and up to ...